Diffuse Large B-Cell Lymphoma
Conditions
Brief summary
Multicentric phase II trial to evaluate efficacy and safety of ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maintenance in patients with refractory/relapsed non-GCB DLBCL non candidates to autologous stem-cell transplantation (ASCT) An extensive biological study will be conducted in order to further characterize this population of DLBCL patients and correlate the response obtained with the biological profile of the tumor.
Detailed description
The use of highly effective rituximab-containing therapy for treating diffuse large B-cell lymphoma (DLBCL) makes it more difficult to salvage relapsed or refractory patients. In addition, patients with advanced age or significant comorbidities, who are consequently not candidates for high-dose consolidative therapy, have a very poor prognosis. Prospective studies investigating new salvage regimens are essential. The combination of rituximab, gemcitabine and oxaliplatin (R-GEMOX) is an effective salvage regimen for patients with relapsing or refractory DLBCL, with a favourable toxicity profile for unfit and/or elderly patients. Ibrutinib, an oral Bruton's tyrosine kinase inhibitor, is a potent killer of ABC DLBCL cell lines in vitro and in xenografts. It is expected that the combination of ibrutinib with R-GEMOX-Dexa could be effective and well tolerated. Thus, it is proposed an open-label, non-randomized, multicentre, phase II trial, to investigate the safety and efficacy of the combination of ibrutinib with rituximab, gemcitabine, oxaliplatine and dexamethasone followed by ibrutinib maintenance as salvage therapy for patients with relapsed or refractory non-GCB DLBCL non-candidates to stem cell transplant.
Interventions
DRUGIbrutinib
Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
DRUGRituximab
Rituximab 375 mg/m2 IV day 1 during 4 cycles.
DRUGGemcitabine
Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
DRUGOxaliplatin
Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
DRUGDexamethasone
Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
Sponsors
Janssen-Cilag, S.A.
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects with confirmed histologically diagnosis of diffuse large B-cell lymphoma. 2. Subjects must be 18 years of age or older. 3. Non-germinal center B-cell-like (GCB) subtype according to Hans algorithm (local laboratories). -A central review will be performed for confirmation of the germinal center B-cell-like, however even when negative results are reported, the patient will still be part of the study if clinical benefit after cycle 4 is documented (stable disease, partial response and complete response). 4. Relapsed or refractory disease after: * at least 1 prior line of therapy that includes rituximab in combination with chemotherapy, or, * after previous ASCT, or, * after reduced intensity conditioning allogeneic transplant, unless patient is receiving immunosuppressive drugs or active graft versus host disease is present at study entry. 5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. 6. Baseline FDG-PET scan demonstrating positive lesions (Deauville 4 or 5) compatible with CT defined anatomical tumor sites. 7. Hematology values must be within the following limits: 1. absolute neutrophil count (ANC) ≥1000/μL independent of growth factor support. 2. platelets ≥100000/μL or ≥50000/μL if bone marrow involvement independent of transfusion support in either situation. 8. Biochemical values within the following limits: 1. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x upper limit of normal (ULN). 2. total bilirubin ≤1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin. 3. serum creatinine ≤2 x ULN or estimated creatinine clearance (CCr) ≥30 mL/min. 9. Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug. 10. Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study. 11. Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing and able to participate in the study.
Exclusion criteria
1. Prior malignancy other than DLBCL, with the exception of adequately treated basal cell or squamous cell skin tumor, in situ cervical cancer, or other tumor from which the patient has been disease free for at least 2 years or which will not limit survival to \< 2 years (Note: these cases must be discussed with the Principal Investigator). 2. Candidates to autologous stem cell transplant. \- Young patients with more than a previous line and refractory could be considered as not suitable for autologous stem cell transplant and, therefore, are eligible for this study. 3. Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety,interfere with the absorption or metabolism of ibrutinib, or put the study outcomes at undue risk. 4. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification. 5. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis,symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. 6. Treatment with any immunotherapy, chemotherapy, radiotherapy, or experimental therapy within 3 weeks before first dose of study drug. 7. Prior treatment with ibrutinib or other BTK inhibitors. 8. Central nervous system (CNS) involvement by lymphoma. 9. History of stroke or intracranial hemorrhage within 6 months prior to randomization. 10. Requires anticoagulation with warfarin or equivalent Vitamin K antagonists. 11. Requires treatment with strong CYP3A inhibitors. 12. Grade ≥2 toxicity (other than alopecia) related to prior anticancer therapy including radiation. 13. Known history of human immunodeficiency virus (HIV), active hepatitis C virus (HCV) (HCV; RNA polymerase chain reaction \[PCR\]-positive) or active Hepatitis B virus (HBV; DNA PCR-positive) infection or any uncontrolled active systemic infection requiring IV antibiotics. Subjects with PCR-negative HBV are permitted in the study. 14. Major surgery within 4 weeks before first dose of study drug. 15. Vaccinated with live, attenuated vaccines within 4 weeks of randomization. 16. Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response (OR) Rate | Treatment responses will be evaluated 30 days after end of study treatment which can be occurred after 2 years and 4 months | Overall Response (OR) rate (complete remission + partial response) measured by PET(Positron Emission Tomography)/CT image scan. OR will be assessed by Lugano Classification: Revised Criteria for Response Assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response Duration | Response duration will be evaluated at any time during the study when tumor response is documented or after end of study treatment which can be occurred after 2 years and 4 months. | Response duration defined as the time from the documentation of tumor response to disease progression or death, in the event of no documented recurrence, or start of a new anti - lymphoma treatment because of refractory or persistent disease. |
| Progression Free Survival | Progression free survival will be evaluated at any time during the study when first documentation of recurrence, progression, or death or after end of study treatment which can be occurred after 2 years and 4 months | Progression free survival defined as the time between start of treatment and the first documentation of recurrence, progression, or death in the event of no documented recurrence, or start of a new anti - lymphoma treatment, due a refractory or persistent disease. Progression is defined using Lugano Classification for response assessment for Non-Hodgkin Lymphoma, defined as Score of 4 or 5 with an increase in uptake intensity over baseline period for Individual lymph nodes/target lymph node masses; New areas of FDG avidity consistent with lymphoma at mid- or end-of-treatment assessment for Extranodal injuries; new injuries; New or recurrent areas of FDG avidity in bone marrow. |
| CR Rate During Induction and Maintenance Phases. | Complete treatment responses will be evaluated 30 days after end of study treatment which can be occurred after 2 years and 4 months | Complete treatment responses evaluation during 21-35 days after initiation of 6 or 8 cycle of study treatment (depend of treatment responses obtained from cycle 4) and 30 days after end of study treatment which can be occurred after 2 years and 4 months |
| Overall Survival | 2 years | Overall survival is defined as the time between the start of treatment and death from any cause. Patients that are withdrawn from the trial or lost of follow-up, will be censored with the date of last contact. Patients who are still alive at the end of the study will be censored at that time. |
| Percentage of Participants That Present Treatment-Related Adverse Events Oxaliplatin and Dexamethasone | 2 years and 4 months | Safety and tolerability will be assessed during any phase of study treatment and 30 days after end of study treatment which can be occurred after 2 years and 4 months and will be classified according to the Common Toxicity CNC |
| Event-free Survival | 2 years and 4 months. | Event-free survival defined as the time between start of treatment and the first documentation of adverse events and serious adverse events graded according to NCI CTCAE v4.0 |
Countries
Spain
Participant flow
Recruitment details
64 patients from 15 different hospitals were registered.
Participants by arm
| Arm | Count |
|---|---|
| Ibrutinib -R-GEMOX-Dexa Subjects will receive Ibrutinib with R-GEMOX-Dexa followed by Ibrutinib maintenance according to:
Induction phase:
* Rituximab 375 mg/m2 IV day 1
* Gemcitabine 1000 mg/m2 IV on day 1 or 2 (at investigator discretion).
* Oxaliplatine 100 mg/m2 on day 1 or 2 (after Gemcitabine administration);
* Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3.
* Ibrutinib 560 mg daily for 14 days.
Responding patients will receive 2 (if CR) or 4 (if PR) additional cycles every 14 days.Patients with SD and ABC profile will receive 4 additional cycles.
Maintenance phase: Responding patients will receive Ibrutinib 560 mg daily - Continuous cycles until a maximum of 2 years, disease progression or unacceptable toxicity.
Ibrutinib: Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
Rituximab: Rituximab 375 mg/m2 IV day 1 during 4 cycles.
Gemcitabine: Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
Oxaliplatin: Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
Dexamethasone: Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days. | 64 |
| Total | 64 |
Baseline characteristics
| Characteristic | Ibrutinib -R-GEMOX-Dexa | — |
|---|---|---|
| Age, Continuous | 67.4 years | — |
| Disease stage at diagnosis I | 1 Participants | — |
| Disease stage at diagnosis II | 9 Participants | — |
| Disease stage at diagnosis III | 5 Participants | — |
| Disease stage at diagnosis IV | 46 Participants | — |
| Disease stage at diagnosis Unk | 3 Participants | — |
| DLBCL type DLBCL rich in T lymphocytes | 3 Participants | — |
| DLBCL type DLBCL without specification | 60 Participants | — |
| DLBCL type Follicular lymphoma | 1 Participants | — |
| ECOG-PS 0 | 23 Participants | — |
| ECOG-PS 1 | 31 Participants | — |
| ECOG-PS 2 | 10 Participants | — |
| International prognostic index (IPI) 0-1 | 6 Participants | — |
| International prognostic index (IPI) 2-3 | 43 Participants | — |
| International prognostic index (IPI) 4-5 | 13 Participants | — |
| International prognostic index (IPI) Unk | 2 Participants | — |
| LDH levels Elevated | 42 Participants | — |
| LDH levels Normal | 20 Participants | — |
| LDH levels Unk | 2 Participants | — |
| Previous lines of treatment | 2 Previous lines of treatment | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Region of Enrollment Spain | 64 participants | — |
| Sex: Female, Male Female | 26 Participants | — |
| Sex: Female, Male Male | 38 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 46 / 64 |
| other Total, other adverse events | 63 / 64 |
| serious Total, serious adverse events | 33 / 64 |
Outcome results
Primary
Overall Response (OR) Rate
Overall Response (OR) rate (complete remission + partial response) measured by PET(Positron Emission Tomography)/CT image scan. OR will be assessed by Lugano Classification: Revised Criteria for Response Assessment.
Time frame: Treatment responses will be evaluated 30 days after end of study treatment which can be occurred after 2 years and 4 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Ibrutinib -R-GEMOX-Dexa | Overall Response (OR) Rate | 36 Participants |
Secondary
CR Rate During Induction and Maintenance Phases.
Complete treatment responses evaluation during 21-35 days after initiation of 6 or 8 cycle of study treatment (depend of treatment responses obtained from cycle 4) and 30 days after end of study treatment which can be occurred after 2 years and 4 months
Time frame: Complete treatment responses will be evaluated 30 days after end of study treatment which can be occurred after 2 years and 4 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Ibrutinib -R-GEMOX-Dexa | CR Rate During Induction and Maintenance Phases. | 25 Participants |
Secondary
Event-free Survival
Event-free survival defined as the time between start of treatment and the first documentation of adverse events and serious adverse events graded according to NCI CTCAE v4.0
Time frame: 2 years and 4 months.
Population: There was 1 (1.6%) patient that ended treatment due to the onset of a new neoplasia but did not require a new therapeutic strategy and was not considered as an EFS event.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ibrutinib -R-GEMOX-Dexa | Event-free Survival | 4.03 months |
Secondary
Overall Survival
Overall survival is defined as the time between the start of treatment and death from any cause. Patients that are withdrawn from the trial or lost of follow-up, will be censored with the date of last contact. Patients who are still alive at the end of the study will be censored at that time.
Time frame: 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ibrutinib -R-GEMOX-Dexa | Overall Survival | 11.67 months |
Secondary
Percentage of Participants That Present Treatment-Related Adverse Events Oxaliplatin and Dexamethasone
Safety and tolerability will be assessed during any phase of study treatment and 30 days after end of study treatment which can be occurred after 2 years and 4 months and will be classified according to the Common Toxicity CNC
Time frame: 2 years and 4 months
Population: percentage of patients that present AE related to the treatment
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Ibrutinib -R-GEMOX-Dexa | Percentage of Participants That Present Treatment-Related Adverse Events Oxaliplatin and Dexamethasone | 55 Participants |
Secondary
Progression Free Survival
Progression free survival defined as the time between start of treatment and the first documentation of recurrence, progression, or death in the event of no documented recurrence, or start of a new anti - lymphoma treatment, due a refractory or persistent disease. Progression is defined using Lugano Classification for response assessment for Non-Hodgkin Lymphoma, defined as Score of 4 or 5 with an increase in uptake intensity over baseline period for Individual lymph nodes/target lymph node masses; New areas of FDG avidity consistent with lymphoma at mid- or end-of-treatment assessment for Extranodal injuries; new injuries; New or recurrent areas of FDG avidity in bone marrow.
Time frame: Progression free survival will be evaluated at any time during the study when first documentation of recurrence, progression, or death or after end of study treatment which can be occurred after 2 years and 4 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ibrutinib -R-GEMOX-Dexa | Progression Free Survival | 4.1 months |
Secondary
Response Duration
Response duration defined as the time from the documentation of tumor response to disease progression or death, in the event of no documented recurrence, or start of a new anti - lymphoma treatment because of refractory or persistent disease.
Time frame: Response duration will be evaluated at any time during the study when tumor response is documented or after end of study treatment which can be occurred after 2 years and 4 months.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ibrutinib -R-GEMOX-Dexa | Response Duration | 6.5 months |